Fassio, E.; Colombato, L.; Gualano, G.; Perez, S.; Puga-Tejada, M.; Landeira, G.
Hepatocellular Carcinoma After HCV Eradication with Direct-Acting Antivirals: A Reappraisal Based on New Parameters to Assess the Persistence of Risk. Cancers 2025, 17, 1018.
https://doi.org/10.3390/cancers17061018
AMA Style
Fassio E, Colombato L, Gualano G, Perez S, Puga-Tejada M, Landeira G.
Hepatocellular Carcinoma After HCV Eradication with Direct-Acting Antivirals: A Reappraisal Based on New Parameters to Assess the Persistence of Risk. Cancers. 2025; 17(6):1018.
https://doi.org/10.3390/cancers17061018
Chicago/Turabian Style
Fassio, Eduardo, Luis Colombato, Gisela Gualano, Soledad Perez, Miguel Puga-Tejada, and Graciela Landeira.
2025. "Hepatocellular Carcinoma After HCV Eradication with Direct-Acting Antivirals: A Reappraisal Based on New Parameters to Assess the Persistence of Risk" Cancers 17, no. 6: 1018.
https://doi.org/10.3390/cancers17061018
APA Style
Fassio, E., Colombato, L., Gualano, G., Perez, S., Puga-Tejada, M., & Landeira, G.
(2025). Hepatocellular Carcinoma After HCV Eradication with Direct-Acting Antivirals: A Reappraisal Based on New Parameters to Assess the Persistence of Risk. Cancers, 17(6), 1018.
https://doi.org/10.3390/cancers17061018
